Trial intelligence / Profile preview

Phase IIIb randomized double-blind trial of ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197) in 4–6-year-old children

CTR20232526Phase 3Completed

Sponsor
CanSino Biologics Inc.
Start
Aug 2023
Modality
Vaccines & Immunotherapeutics
Countries
1
01

Overview

A Phase 3 trial of acyw135 meningococcal conjugate vaccine crm197 in meningococcal meningitis, sponsored by CanSino Biologics Inc.. Started Aug 2023; status: completed.

02

Drugs

acyw135 meningococcal conjugate vaccine crm197
03

Conditions

meningococcal meningitis

Beyond the preview

Go deeper on CTR20232526.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20232526.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call